ACCESSWIRE
03 Aug 2022, 22:25 GMT+10
TORONTO, ON / ACCESSWIRE / August 3, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that its executive management will participate in the upcoming BTIG Biotechnology Conference being held in New York, NY on August 8-9, 2022. The hybrid event will be held both virtually and in-person.
Attendees who are interested in meeting with the company should contact their BTIG representative or Edesa directly via email at investors@edesabiotech.com.
About Edesa Biotech
Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that Edesa is developing as a treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure and the leading cause of death among Covid-19 patients. EB01 is an sPLA2 inhibitor being developed as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. Sign up for news alerts. Connect with us on Twitter and LinkedIn.
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'will,' 'would,' 'could,' 'should,' 'might,' 'potential,' or 'continue' and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as Covid-19. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Contacts
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
investors@edesabiotech.com
Chuck Padala
LifeSci Advisors
chuck@lifesciadvisors.com
SOURCE: Edesa Biotech
Get a daily dose of Toronto Telegraph news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Toronto Telegraph.
More InformationSYDNEY, NSW, Australia - Stocks in Japan surged on Friday as investors and traders returned to their desks after a ...
LONDON, England: A survey conducted by YouGov and consultancy Cebr reported that UK consumer confidence slowly rose in July, after ...
DHAKA, Bangladesh - Foreign Minister AK Abdul Momen has stated that the Switzerland Ambassador to Bangladesh Nathalie Chuard's claims that ...
NEW YORK, New York - Stocks closed mixed the world over Thursday as investors struggled to get a clear picture ...
NEW YORK CITY, New York: In another frustrating day for U.S. travelers, on the morning of August 9, 153 flights ...
JAKARTA, Indonesia: A senior cabinet minister in Indonesia has told CNBC Indonesia that U.S. carmaker Tesla has signed contracts worth ...
OTTAWA, Ontario: Military trainers from Canada will head to the United Kingdom to teach Ukrainians new techniques for fighting the ...
The crucial part for the Nord Stream 1 pipeline has been stuck in Germany following repairs in CanadaGerman Chancellor Olaf ...
The tennis great was easily beaten in the second round of the Canadian OpenTennis icon Serena Williams' farewell to the ...
It was a loss that made the biggest news at the National Bank Open in Toronto on Wednesday as Serena ...
The field will be the star when the Chicago Cubs play the Cincinnati Reds in the second annual "Field of ...
Just a day after announcing she plans to wind down her tennis career, Serena Williams exited the National Bank Open ...